Skip to main content

Inmune Bio, Inc 8-K, filed Oct 21, 2026

Inmune Bio, Inc. (INMB)

8-K 2026-10-21 For: 2026-10-21
View Original
Added on October 21, 2026

About this 8-K

Inmune Bio, Inc filed this 8-K on October 21, 2026.

INmune Bio submitted its final pre-Marketing Authorisation Application package to the UK MHRA for Ebstrocel on October 20, 2026. The company targets a full MAA submission in early February 2027, with potential UK approval in mid-2027, subject to MHRA review. It also entered into a Master Services Agreement with Uniphar Durbin Ireland Limited and expects to submit a U.S. BLA in Q2 2027. AI summary

Items reported

  • Item 7.01: Regulation FD disclosure
  • Item 8.01: Other events
  • Item 9.01: Financial statements and exhibits